BLSM (BlossomHill Therapeutics) EV-to-OCF: (As of Aug. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLSM BlossomHill Therapeutics Inc BLSM
8 GF Score
Price $16.02
View Full Analysis

What is BlossomHill Therapeutics EV-to-OCF?

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, BlossomHill Therapeutics's Enterprise Value is $372.90 Mil. BlossomHill Therapeutics does not have enough years/quarters to calculate its Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate BlossomHill Therapeutics's EV-to-OCF at this moment.

The historical rank and industry rank for BlossomHill Therapeutics's EV-to-OCF or its related term are showing as below:

BLSM' s EV-to-OCF Range Over the Past 10 Years
Min: -8.24   Med: 0   Max: 0
Current: -7.95
BLSM's EV-to-OCF is ranked worse than
100% of 1405 companies
in the Biotechnology industry
Industry Median: -3.45 vs BLSM: -7.95

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-08-10), BlossomHill Therapeutics's stock price is $16.02. BlossomHill Therapeutics does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate BlossomHill Therapeutics's PE Ratio (TTM) at this moment.

BlossomHill Therapeutics  (NAS:BLSM) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

BlossomHill Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=16.02/
=

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.

BlossomHill Therapeutics EV-to-OCF Related Terms

BlossomHill Therapeutics EV-to-OCF Historical Data

* Premium members only.

The historical data trend for BlossomHill Therapeutics's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BlossomHill Therapeutics EV-to-OCF Chart

BlossomHill Therapeutics Annual Data
Trend Dec24 Dec25
EV-to-OCF
0.00 0.00

BlossomHill Therapeutics Semi-Annual Data
Dec24 Dec25
EV-to-OCF 0.00 0.00

BLSM vs : EV-to-OCF Comparison

For the Biotechnology subindustry, BlossomHill Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BlossomHill Therapeutics EV-to-OCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BlossomHill Therapeutics's EV-to-OCF distribution charts can be found below:

* The bar in red indicates where BlossomHill Therapeutics's EV-to-OCF falls into.


BLSM
8GF Score
BlossomHill Therapeutics Inc BLSM
EV-to-OCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BlossomHill Therapeutics EV-to-OCF Calculation

BlossomHill Therapeutics's EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=372.902/
=

BlossomHill Therapeutics Business Description

Comparable Companies
Address 10255 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
8GF Score

Get the complete analysis for BLSM

EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.02
Price